317 related articles for article (PubMed ID: 31213803)
21. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
22. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Maakaron JE; Mims AS
Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
[TBL] [Abstract][Full Text] [Related]
23. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Chen EC; Fathi AT; Brunner AM
Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
[TBL] [Abstract][Full Text] [Related]
24. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
25. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin.
Dicko A; Kwak S; Frazier AA; Mayer LD; Liboiron BD
Int J Pharm; 2010 May; 391(1-2):248-59. PubMed ID: 20156541
[TBL] [Abstract][Full Text] [Related]
26. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia.
Blair HA
Drugs; 2018 Dec; 78(18):1903-1910. PubMed ID: 30511323
[TBL] [Abstract][Full Text] [Related]
27. Research on the preparation process of the cytarabine/daunorubicin dual-encapsulation liposome and its physicochemical properties and performances in vitro/vivo.
Liu B; Zhang J; Liu Z; Wang P; Zhang Y; He H; Yin T; Gou J; Tang X
Int J Pharm; 2023 Nov; 646():123500. PubMed ID: 37820944
[TBL] [Abstract][Full Text] [Related]
28. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
[TBL] [Abstract][Full Text] [Related]
29. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
[TBL] [Abstract][Full Text] [Related]
30. CPX-351 exhibits hENT-independent uptake and can be potentiated by fludarabine in leukaemic cells lines and primary refractory AML.
Anderson E; Mehta P; Heywood J; Rees B; Bone H; Robinson G; Reynolds D; Salisbury V; Mayer L
Leuk Res; 2018 Nov; 74():121-129. PubMed ID: 30119908
[TBL] [Abstract][Full Text] [Related]
31. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
[TBL] [Abstract][Full Text] [Related]
32. Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells.
Di Y; Wasan EK; Cawthray J; Wasan KM
Drug Dev Ind Pharm; 2019 Jan; 45(1):21-26. PubMed ID: 30113235
[TBL] [Abstract][Full Text] [Related]
33. CPX-351 (vyxeos) in AML.
Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
[TBL] [Abstract][Full Text] [Related]
34. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Talati C; Lancet JE
Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
[TBL] [Abstract][Full Text] [Related]
35. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Howell G; Oliai C; Schiller G
Anticancer Res; 2018 Dec; 38(12):6927-6930. PubMed ID: 30504411
[TBL] [Abstract][Full Text] [Related]
36. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351.
Donnette M; Hamimed M; Ciccolini J; Berda-Haddad Y; Kaspi E; Venton G; Lacarelle B; Costello R; Ouafik L; Farnault L; Fanciullino R
J Control Release; 2021 Oct; 338():244-252. PubMed ID: 34416320
[TBL] [Abstract][Full Text] [Related]
38. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Kolitz JE; Strickland SA; Cortes JE; Hogge D; Lancet JE; Goldberg SL; Villa KF; Ryan RJ; Chiarella M; Louie AC; Ritchie EK; Stuart RK
Leuk Lymphoma; 2020 Mar; 61(3):631-640. PubMed ID: 31760835
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial.
Cortes JE; Lin TL; Asubonteng K; Faderl S; Lancet JE; Prebet T
J Hematol Oncol; 2022 Oct; 15(1):155. PubMed ID: 36289532
[TBL] [Abstract][Full Text] [Related]
40. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]